What is Applied Proteomics?
Applied Proteomics, Inc. is a specialized biotechnology firm focused on the development of advanced protein-based diagnostic tests. Its flagship offering, the SimpliPro Colon Test, represents a significant advancement in colorectal wellness assessment. By evaluating 11 specific protein markers, the test provides healthcare providers with a comprehensive risk assessment for esophageal cancer and advanced adenoma. The company's strategic focus is to improve patient adherence to colonoscopy procedures by integrating its blood-based diagnostic tools into routine clinical examinations, thereby bridging the gap between early detection and patient compliance.
How much funding has Applied Proteomics raised?
Applied Proteomics has raised a total of $54.5M across 3 funding rounds:
Series A
$4M
Series B
$22.5M
Series C
$28M
Series A (2007): $4M, investors not publicly disclosed
Series B (2012): $22.5M led by Vulcan Capital Management and Domain Associates
Series C (2013): $28M supported by Genting Berhad, Domain Associates, and Vulcan Capital Management
Key Investors in Applied Proteomics
Genting Berhad
Genting Group is a prominent holding company established in 1965, managing a diverse portfolio of international resorts and leisure assets.
Domain Associates
An investment advisory firm founded in 1985 that specializes in biotech and life sciences, with a track record of supporting numerous diagnostic and biopharmaceutical companies.
Vulcan Capital Management
A diversified private equity firm that targets middle-market assets and unique investment opportunities, leveraging deep market knowledge to drive value for institutional investors.
What's next for Applied Proteomics?
Looking ahead, the strategic deployment of the $28M will likely focus on expanding the commercial footprint of the SimpliPro platform and potentially diversifying the company's diagnostic portfolio. As the firm transitions from a development-heavy phase to a broader market penetration strategy, the focus will shift toward clinical validation and integration into large-scale healthcare networks. The backing from seasoned investors provides the necessary runway to navigate the complex regulatory environment of the diagnostics sector while maintaining a competitive edge in protein-marker research. Future growth will be predicated on the company's ability to demonstrate superior clinical outcomes and cost-effectiveness to healthcare providers and payers alike.
See full Applied Proteomics company page
